• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Cumulative number of Civil Money Penalties filed for the FY against Tobacco Retailers (excluding internet based)

Dictionary: The Family Smoking Prevention and Tobacco Control Act amended the Federal Food, Drug, and Cosmetic Act and provided the FDA with a broad set of sanctions for violations of the law. Such sanctions may include: warning letter, civil money penalty, import alert, seizure, injunction, and criminal prosecution.

Civil Money Penalties are assessed against tobacco product retailers not in compliance with tobacco product requirements. For more information about the agency’s current policies with respect to civil money penalties for retailers who are in violation, please see CTP’s website Guidance, Compliance & Regulatory Information, to find the guidance entitled, “Guidance for FDA and Tobacco Retailers Civil Money Penalties and No-Tobacco-Sale Orders For Tobacco Retailers.”

Information is current as of March 30, 2013

Fiscal Year - 2013

Skip graphic and jump to text data

TimeTargetNumber
Oct 2012N/A0
Nov 2012N/A18
Dec 2012N/A40
Jan 2013N/A79
Feb 2013N/A140
Mar 2013N/A194
Apr 2013N/A247
May 2013N/A307
Jun 2013N/A353
Jul 2013N/A378
Aug 2013N/A459
Sep 2013N/A537

FY 2013 Cumulative Total: 537

Number of Civil Money Penalties filed in the month against Tobacco Retailers (excluding internet based)

Fiscal Year - 2013
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2012N/A0
Nov 2012N/A18
Dec 2012N/A22
Jan 2013N/A39
Feb 2013N/A61
Mar 2013N/A54
Apr 2013N/A53
May 2013N/A60
Jun 2013N/A46
Jul 2013N/A25
Aug 2013N/A81
Sep 2013N/A78

FY 2013 Total: 537

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.